Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Immuron ( (IMRN) ).
On January 19, 2026, Immuron reported unaudited first-half fiscal 2026 global sales of AUD$4.2 million for its Travelan product, a 5% increase on the prior comparative period, with second-quarter sales up 11% sequentially to AUD$2.2 million, underscoring ongoing momentum in its core gastrointestinal health franchise. The company’s growth was driven chiefly by Australia, where H1 sales rose 13% to AUD$3.3 million and Q2 sales climbed 11%, supported by intensified digital marketing, expanded pharmacy ranging and higher outbound travel, while Immuron also launched its new ProIBS product nationally late in 2025 to broaden its gastrointestinal portfolio. In the U.S., H1 Travelan sales increased 17% to AUD$0.9 million, aided by an upgraded Amazon presence and heavier social media marketing, and in Canada, although H1 sales fell sharply year-on-year following an earlier pipeline fill, Q2 sales rebounded 191% quarter-on-quarter as consumer promotions gained traction; the planned FY26 launch into Jean Coutu pharmacies is expected to further strengthen Immuron’s position in the Canadian pharmacy channel. These trends highlight Immuron’s progress in scaling its over-the-counter gastrointestinal brands across key markets, leveraging digital campaigns, expanded retail distribution and new product introductions to support future revenue growth.
The most recent analyst rating on (IMRN) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Immuron stock, see the IMRN Stock Forecast page.
Spark’s Take on IMRN Stock
According to Spark, TipRanks’ AI Analyst, IMRN is a Underperform.
Immuron’s stock score is primarily impacted by its poor financial performance and bearish technical indicators. The company’s negative profitability and cash flow challenges are significant concerns. The technical analysis suggests oversold conditions, but the lack of positive valuation metrics further weighs down the score.
To see Spark’s full report on IMRN stock, click here.
More about Immuron
Immuron Limited (ASX: IMC; NASDAQ: IMRN) is an Australian biopharmaceutical company focused on developing and commercializing orally delivered, targeted polyclonal antibody therapies for inflammatory-mediated and infectious diseases. Its lead commercial product, Travelan, is an over-the-counter immune supplement based on hyper-immune bovine colostrum antibodies that aims to reduce the risk of travelers’ diarrhea and other minor gastrointestinal disorders, and is marketed as a listed medicine in Australia, a licensed natural health product in Canada, and a dietary supplement in the United States.
Average Trading Volume: 579,237
Technical Sentiment Signal: Sell
Current Market Cap: $8.99M
See more data about IMRN stock on TipRanks’ Stock Analysis page.